Rheumatoid Purpura in Children: a Multicenter Observational Study of Pediatric Emergency Department Management and Follow-up by Primary Care Physicians

NCT05737056 | Completed

• 2 other identifiers: GHRMSA 12782022-A02687-36
• Study Type: observational
• Target: 66
• Locations: 1 country
• Sites: 2

Brief Summary

The main objective of this study is to describe the management of children with rheumatoid purpura from admission to the pediatric emergency room to follow-up by primary care physicians after hospital discharge.

Conditions

Rheumatoid Purpura

Outcome Measures

Primary Outcomes (1)

• Compliance with the recommendations for the management of rheumatoid purpura

  Up to two years after hospital discharge

Secondary Outcomes (1)

• Knowledge assessment questionnaire regarding rheumatoid purpura

  At the beginning of the study

Study Arms (1)

Children diagnosed with rheumatoid purpura at the pediatric emergency department

Children diagnosed with rheumatoid purpura from admission to the pediatric emergency department up to two years of follow-up by general practitioners after hospital discharge.

Other: Management of rheumatoid purpura

Interventions

Management of rheumatoid purpura OTHER

Collection of data on the management in pediatric emergency departments (method of diagnosis, complementary examinations, proposed treatment, number of hospitalizations, follow-up after hospital discharge).

Children diagnosed with rheumatoid purpura at the pediatric emergency department

Eligibility Criteria

• Age: 0 Years - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Patients will be identified by the Medical Information Department of each site. The study will be conducted on patients who have been managed for rheumatoid purpura within the last two years at one of the three participating centers.

You may qualify if:

• Underaged patient diagnosed with rheumatoid purpura during a visit to the pediatric emergencies of Mulhouse, Colmar and Strasbourg
• No objection to the study from the two holders of parental authority

You may not qualify if:

• \- Patient followed in the context of a genetic or malformative pathology, an immune deficiency, or a cancer

Sponsors & Collaborators

• Groupe Hospitalier de la Region de Mulhouse et Sud Alsace: lead

Study Sites (2)

Hôpitaux Civils de Colmar

Colmar, 68000, France

Location

Hôpital de Hautepierre

Strasbourg, 67200, France

Location

Related Links

• Study results

MeSH Terms

Conditions

IgA Vasculitis

Condition Hierarchy (Ancestors)

Vasculitis; Vascular Diseases; Cardiovascular Diseases; Purpura; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemostatic Disorders; Hemorrhagic Disorders; Skin Diseases, Vascular; Skin Diseases; Skin and Connective Tissue Diseases; Immune Complex Diseases; Hypersensitivity; Immune System Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Skin Manifestations; Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 10, 2023
• First Posted: February 21, 2023
• Study Start: May 9, 2023
• Primary Completion: July 28, 2023
• Study Completion: July 28, 2023
• Last Updated: November 20, 2025

Record last verified: 2023-10

Locations

FR (2)